Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Mushroom Extract Receives IND From FDA - Nutraceuticals World

What are you searching for?

Sign in
Market Updates

Mushroom Extract Receives IND From FDA

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

The Tradeworks Group, Inc., Brattleboro, VT, has been granted an Investigational New Drug (IND) number by FDA in conjunction with a government funded human clinical study on breast cancer for one of the company’s proprietary medicinal mushroom extracts. Tradeworks is the exclusive supplier of the patented maitake extract to be used in the multi-phase, three-year study. The same extract is marketed in North America by dietary supplement companies under the trade name MaitakeGold404®. Unlike most compounds approved for an IND, MaitakeGold 404 is not a drug, but rather an all-natural extract derived from the maitake mushroom. It is, however, being subjected to the same scrutiny as a drug for the purposes of this study.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters